FDA Clears Tris Pharma’s Onyda XR for ADHD: A Daily, Long-Acting Oral Liquid Medication
FDA Approves Tris Pharma’s Onyda XR for ADHD Treatment The U.S. Food and Drug Administration (FDA) has granted approval to Tris Pharma for its innovative medication, Onyda XR, which is designed to treat Attention Deficit/Hyperactivity Disorder (ADHD) in patients aged six years and older. Onyda XR is a once-daily, extended-release oral suspension that represents a […]
FluoGuide Reports Q1 2024 Results for Targeted Urology Solutions
FluoGuide A/S, a leading provider of innovative solutions for precision-guided cancer surgery, has published its interim report for the first quarter of 2024. The report highlights the company’s significant progress in advancing its pipeline of targeted fluorescent imaging agents and expanding its market presence. During this period, FluoGuide achieved key milestones in the clinical development […]
Evotec Partners to Identify Therapeutic Targets for Obesity, Metabolic Diseases
Here is the SEO optimized article for a biotech publication, using HTML tags for proper formatting on WordPress: Evotec SE has announced a groundbreaking partnership with Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to advance research in the field of obesity and metabolic diseases. This collaboration […]